Esra Baskın, Utku Dönger, Meraj Alam Siddiqui, Figen Özçay, Elif Sahin Eroglu, Adem Şafak, Emre Karakaya, Mehmet Haberal
{"title":"Therapeutic Plasma Exchange in Pediatric Transplant and Organ Failure: Analysis of Indications, Adverse Events, and Clinical Outcomes.","authors":"Esra Baskın, Utku Dönger, Meraj Alam Siddiqui, Figen Özçay, Elif Sahin Eroglu, Adem Şafak, Emre Karakaya, Mehmet Haberal","doi":"10.6002/ect.MESOT2025.O58","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Therapeutic plasma exchange has become an increasingly important extracorporeal therapy in pediatric intensive care and transplant settings. However, evaluations in large real-world pediatric cohorts of its effectiveness and safety across multiple indications remain limited. In this 5 -year single -center study, we provided our experience with therapeutic plasma exchange in critically ill children and assessed clinical outcomes, indications, and procedure -related complications.</p><p><strong>Materials and methods: </strong>This retrospective observational study included 88 pediatric patients who underwent 702 therapeutic plasma exchange sessions in the pediatric transplant and nephrology intensive care unit of Başkent University Hospital (Ankara, Turkey) between December 2018 and December 2023. Indications were classified according to new American Society for Apheresis categories. We analyzed demographic data, indications, replacement fluids, treatment response, and adverse events.</p><p><strong>Results: </strong>Median age of the 88 pediatric patients who underwent 702 therapeutic plasma exchange sessions was 7.5 years (range, 0 -18 y ), and 52.3 % of patients were male. Fresh frozen plasma was used in 89.8 % of sessions and albumin in 23.9 %. The most frequent indications for therapeutic plasma exchange were posttransplant hepatic dysfunction (36.4 % ) and acute or chronic liver failure (28.4 % ), followed by antibody -mediated renal disease (13.6 % ) and multiorgan failure or sepsis (8 % ). Overall, 73 of 88 patients achieved complete or partial improvement, corresponding to a favorable response rate of 82.9 %. Renal transplant-related indications demonstrated higher response rates compared with liver -related conditions (91 % vs 78.9 % ). No life-threatening or procedure -terminating complications occurred; minor adverse events included hypotension, fever, allergic reactions, and thrombosis.</p><p><strong>Conclusions: </strong>Therapeutic plasma exchange is a safe and effective supportive therapy for critically ill pediatric patients across a wide range of indications. When performed in experienced centers with close monitoring, complication rates are low. Multicenter prospective studies are needed to establish standardized protocols and further clarify disease-specific outcomes.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"24 Suppl 2","pages":"166-171"},"PeriodicalIF":0.7000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6002/ect.MESOT2025.O58","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Therapeutic plasma exchange has become an increasingly important extracorporeal therapy in pediatric intensive care and transplant settings. However, evaluations in large real-world pediatric cohorts of its effectiveness and safety across multiple indications remain limited. In this 5 -year single -center study, we provided our experience with therapeutic plasma exchange in critically ill children and assessed clinical outcomes, indications, and procedure -related complications.
Materials and methods: This retrospective observational study included 88 pediatric patients who underwent 702 therapeutic plasma exchange sessions in the pediatric transplant and nephrology intensive care unit of Başkent University Hospital (Ankara, Turkey) between December 2018 and December 2023. Indications were classified according to new American Society for Apheresis categories. We analyzed demographic data, indications, replacement fluids, treatment response, and adverse events.
Results: Median age of the 88 pediatric patients who underwent 702 therapeutic plasma exchange sessions was 7.5 years (range, 0 -18 y ), and 52.3 % of patients were male. Fresh frozen plasma was used in 89.8 % of sessions and albumin in 23.9 %. The most frequent indications for therapeutic plasma exchange were posttransplant hepatic dysfunction (36.4 % ) and acute or chronic liver failure (28.4 % ), followed by antibody -mediated renal disease (13.6 % ) and multiorgan failure or sepsis (8 % ). Overall, 73 of 88 patients achieved complete or partial improvement, corresponding to a favorable response rate of 82.9 %. Renal transplant-related indications demonstrated higher response rates compared with liver -related conditions (91 % vs 78.9 % ). No life-threatening or procedure -terminating complications occurred; minor adverse events included hypotension, fever, allergic reactions, and thrombosis.
Conclusions: Therapeutic plasma exchange is a safe and effective supportive therapy for critically ill pediatric patients across a wide range of indications. When performed in experienced centers with close monitoring, complication rates are low. Multicenter prospective studies are needed to establish standardized protocols and further clarify disease-specific outcomes.
目的:治疗性血浆交换已成为儿科重症监护和移植环境中越来越重要的体外治疗方法。然而,在现实世界的大型儿科队列中,对其跨多种适应症的有效性和安全性的评估仍然有限。在这项为期5年的单中心研究中,我们提供了治疗性血浆置换治疗危重儿童的经验,并评估了临床结果、适应症和手术相关并发症。材料和方法:本回顾性观察性研究纳入了2018年12月至2023年12月期间在ba肯特大学医院(土耳其安卡拉)儿科移植和肾病重症监护室接受702次治疗性血浆交换的88例儿科患者。适应症根据新的美国采血学会分类进行分类。我们分析了人口统计学数据、适应症、补液、治疗反应和不良事件。结果:88例接受702次血浆交换治疗的儿童患者的中位年龄为7.5岁(范围0 -18岁),52.3%的患者为男性。89.8%的患者使用新鲜冷冻血浆,23.9%的患者使用白蛋白。治疗性血浆置换最常见的适应症是移植后肝功能障碍(36.4%)和急性或慢性肝衰竭(28.4%),其次是抗体介导的肾脏疾病(13.6%)和多器官功能衰竭或败血症(8%)。总体而言,88例患者中有73例获得完全或部分改善,相应的有利缓解率为82.9%。与肝脏相关疾病相比,肾移植相关适应症的有效率更高(91% vs 78.9%)。未发生危及生命或终止手术的并发症;轻微的不良反应包括低血压、发烧、过敏反应和血栓形成。结论:治疗性血浆置换是一种安全有效的支持治疗,适用于各种适应症的危重儿科患者。如果在经验丰富的中心进行手术并进行密切监测,并发症发生率很低。需要多中心前瞻性研究来建立标准化方案并进一步明确疾病特异性结果。
期刊介绍:
The scope of the journal includes the following:
Surgical techniques, innovations, and novelties;
Immunobiology and immunosuppression;
Clinical results;
Complications;
Infection;
Malignancies;
Organ donation;
Organ and tissue procurement and preservation;
Sociological and ethical issues;
Xenotransplantation.